Study of EMB-001 as a Potential Smoking Cessation Treatment
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone
(Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®;
now marketed as oxazepam (generic) only).
This is an open-label study in up to 50 adult subjects to help smokers abstain from smoking
during a 12-week trial period.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Embera NeuroTherapeutics, Inc.
Collaborators:
Foundation for a Smoke-Free World Rose Research Center, LLC